revenu million
valu usd unless otherwis note
view downgrad sector perform valuat
remain bullish compani fundament high growth
prospect core cystic fibrosi franchis strong adopt launch
drug trikafta good insul like lead
revenu beat option broaden high-scienc pipelin
could provid addit lt revenu upsid also believ
compani remain attract investor seek clean high-qual
large-cap stori low-risk growth within sector like
continu view defens volatil environ howev
share near time high ytd believ
attract attribut form cornerston posit thesi
start play limit nt catalyst see fewer
driver addit nt upsid inflect continu view
core biotech hold would wait better entri point
perhap context broader market sell-off add posit
adjust price target upward better reflect
favor attribut context space market broadli
continu expect cf franchis outperform still see
rapid expect convers cf portfolio trikafta estimate
sale vs consensu believ enabl
bottom-lin beat vs con although potenti slowdown
due remain difficult predict continu believ cf
product well-insul environ even allow
growth reduct see full year sale still substanti beat
consensu guidanc estimate vs con guidanc
see visibl toward annual cf sale long term
maintain high margin valuat though
expect may alreadi price
pipelin readout limit nt continu hold divers lt
potenti remain enthusiast program
leverag similar mechanist poc principl cf program
shown promis preclin data view expect
compani success navig evolv registr requir
though near-term data could push due pandem
believ compani crispr kidney program interest
good scientif rational remain earlier-stag higher risk
ascrib signific valu though contribut
out-year termin growth rate assumpt dcf --
success de-risk program could lead upsid
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
bullish prospect vrtx trikafta come
earli approv particularli concern
long-term threat franchis given high bar
limit potenti competitor believ
high-growth prospect potenti best-in-class margin
confer scarciti valu said believ share
bake optim addit appreci
requir clearer de-risk clinic prospect revenu
opportun rest pipelin
posit leader high-growth high-margin cf space
led kalydeco orkambi symdeko trikafta trikafta
earli approv strong launch could support similarli
rapid path eu high bar potenti futur
risk price pressur competit entrant could
outsiz neg impact out-year revenu
market opportun may take time build
program remaind pipelin earli stage and/or higher
potenti catalyst addit updat ex-u
reimburs approv therapi potenti
trikafta approv eu data ph ii
studi aatd
bloomberg capit market estim upside/downside/target
base case assum chanc trikafta expans
europ improv persistence/compli symdeko
continu expans lower age rang
price target deriv dcf analysi
discount rate termin growth rate
success expans trikafta europ better-than-
expect ex-u reimburs price power ex-
cf pipelin success would lead upsid estim
upsid scenario potenti dcf-base valuat
would
failur get trikafta approved/reimburs eu
emerg competit reduc long-term market share
emerg safeti signal erod price power
would lead downsid estim downsid
scenario potenti dcf-base valuat would
thousand except per share probability-weight revenu total revenu product expenses- oper expens incom net- net pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand exhibit cystic fibrosi us revenu build
pt pt age penetr kalydeco trikafta pt age penetr function pt age penetr function- splice pt age penetr pt age penetr pt age penetr orkambi symdeko trikafta pt age penetr orkambi symdeko trikafta pt age penetr pt price gross price price per kalydeco sale pt price gross price price per orkambi sale pt price gross price price per symdeko sale pt price gross price price per trikafta sale exhibit cystic fibrosi revenu build
pt pt age penetr kalydeco trikafta pt age penetr function pt age penetr pt age penetr pt age penetr orkambi symdeko trikafta pt age penetr orkambi symdeko trikafta pt age penetr penetr trikafta pt price price per kalydeco sale int pt price price per orkambi sale int pt price price per symdeko sale int pt price per trikafta sale int
price target deriv dcf analysi base busi discount
rate termin growth rate price target support sector perform rate
risk rate price target
risk includ lower-than-expect commerci uptak tez/iva price pressur cf
competit emerg safeti issu tripl combo
global biotechnolog compani focus develop
small molecul drug seriou unmet diseas compani previous develop
drug fda approv hiv hep multipl approv drug
includ kalydeco orkambi symdeko trikafta treatment variou mutat
cystic fibrosi develop pipelin addit cf drug popul
current drug address addit vertex work build pipelin
beyond cf next year vertex aspir becom fulli integr
biopharmaceut compani discoveri commerci global sale
market commerci infrastructur
analyst respons prepar research report receiv compens base upon variou factor includ
total revenu member compani capit market affili portion gener
invest bank activ member compani capit market affili
pleas note current conflict disclosur may differ public date set forth
report access current conflict disclosur client refer http //www rbccm com/gldisclosure/publicweb/
send request cm research publish bay street royal bank plaza
capit market llc make market secur vertex pharmaceut incorpor
explan capit market equiti rate system
analyst sector univers compani analyst provid research coverag accordingli rate assign
particular stock repres sole analyst view stock perform next month rel
outperform expect materi outperform sector averag month
sector perform sp return expect line sector averag month
under-perform return expect materi sector averag month
restrict polici preclud certain type commun includ invest recommend
act advisor certain merger strateg transact certain circumst
rate nr rate price target estim remov due applic legal regulatori polici constraint
may includ capit market act advisori capac involv compani
march capit market discontinu top pick rate top pick rate secur repres analyst best
idea sector expect provid signific absolut return month favor risk-reward ratio top pick
rate secur reassign outperform rate secur categori secur expect materi
outperform sector averag month
specul risk rate reflect secur lower level financi oper predict illiquid share trade volum
high balanc sheet leverag limit oper histori result higher expect financi and/or stock price volatil
distribut rate
purpos rate distribut regulatori rule requir member firm assign rate one three rate categori
 buy hold/neutr sell regardless firm rate categori although capit market rate outperform
sector perform sp under-perform close correspond buy hold/neutr sell respect mean
rate determin rel basi
distribut rate
rate price target histori vertex pharmaceut incorpor us usd
tp top pick outperform sp sector perform under-perform restrict initi research coverag discontinu research coverag
nr rate na avail rl recommend list rl refer date secur place recommend list rl refer date
secur remov recommend list rtg rate
creat bluematrix
refer recommend list recommend histori chart may includ one recommend list model
portfolio maintain wealth manag one affili wealth manag recommend list includ
guid portfolio prime incom rl guid portfolio dividend growth rl guid portfolio adr rl
guid portfolio cap growth rl capit market recommend list includ strategi focu list
fundament equiti weight portfolio abbrevi rl mean date secur place
recommend list abbrevi rl mean date secur remov recommend list
equiti valuat risk
valuat method use determin risk may imped achiev price target cover compani pleas
see recent company-specif research report http //www rbcinsightresearch com send request capit
price target deriv dcf analysi base busi discount rate termin growth
rate price target support sector perform rate
risk rate price target
risk includ lower-than-expect commerci uptak tez/iva price pressur cf competit emerg safeti
issu tripl combo
capit market polici manag conflict interest relat invest research avail us request
access current polici client refer
send request capit market research publish bay street royal bank plaza floor south
tower toronto ontario reserv right amend supplement polici time
dissemin research short-term trade idea
capit market endeavor make reason effort provid research simultan elig client
regard local time zone oversea jurisdict capit market equiti research post proprietari websit
ensur elig client receiv coverag initi chang rate target opinion time manner addit
distribut may done sale personnel via email fax electron mean regular mail client may also
receiv research via third parti vendor capit market also provid elig client access sparc firm
proprietari insight websit via email via third-parti vendor sparc contain market color commentari regard
subject compani firm current provid equiti research coverag research analyst may time time
includ short-term trade idea research report sparc short-term trade idea offer short-term view
secur may trade base market trade event result trade opportun may avail
short-term trade idea may differ price target recommend publish research report reflect
research analyst view long-term one year prospect subject compani result differ time horizon
methodolog and/or factor thu possibl subject compani common equiti consid long-term
sector perform even under-perform might present short-term buy opportun result temporari sell pressur
market convers subject compani common equiti rate long-term outperform could consid suscept
short-term downward price correct short-term trade idea rate part rate system
firm gener intend undertak oblig maintain updat short-term trade idea short-term trade
idea may suitabl investor tailor individu investor circumst object
investor make independ decis regard secur strategi discuss herein pleas contact
invest advisor institut salesperson inform regard capit market research
list recommend compani dissemin prior period pleas click
month histori sparc view http //www rbcinsightresearch com
view express report accur reflect person view respons analyst
subject secur issuer part compens respons analyst name herein directli
indirectli relat specif recommend view express respons analyst report
global industri classif standard gic develop exclus properti servic mark inc standard poor financi servic
llc licens use neither parti involv make compil gic gic classif make express impli
warranti represent respect standard classif result obtain use thereof parti herebi expressli disclaim warranti
origin accuraci complet merchant fit particular purpos respect standard classif without limit forego
event shall affili third parti involv make compil gic gic classif liabil direct indirect special
punit consequenti damag includ lost profit even notifi possibl damag
refer herein libor libo rate libor abbrevi mean london interbank offer rate administ benchmark administr
person take administr rate
capit market busi name use certain branch subsidiari royal bank canada includ dominion secur inc
capit market llc europ limit royal bank canada hong kong branch royal bank canada sydney branch inform contain
report compil capit market sourc believ reliabl represent warranti express impli made royal
canada capit market affili person accuraci complet correct opinion estim contain
report constitut capit market judgement date report subject chang without notic provid good faith without
legal respons noth report constitut legal account tax advic individu tailor invest advic materi prepar gener
circul client prepar without regard individu financi circumst object person receiv invest
servic contain report may suitabl recommend consult independ invest advisor doubt
suitabl invest servic report offer sell solicit offer buy secur past perform guid
futur perform futur return guarante loss origin capit may occur capit market research analyst compens base
part overal profit capit market includ profit attribut invest bank revenu everi provinc canada state
 countri throughout world law regul type secur invest product may offer
resid well process result secur discuss report may elig sale jurisdict capit
market may restrict publish research report time time due regulatori restrict and/ intern complianc polici case
latest publish research report avail client may reflect recent materi chang applic industri and/or applic subject compani
capit market research report current date set forth research report report circumst
constru solicit act secur broker dealer jurisdict person compani legal permit carri busi
secur broker dealer jurisdict full extent permit law neither capit market affili person accept
liabil whatsoev direct indirect consequenti loss aris connect use report inform contain herein
matter contain document may reproduc copi mean without prior written consent capit market instanc
addit inform avail request
public approv capit market llc member finra nyse sipc regist broker-deal accept
respons report dissemin unit state recipi report regist broker-deal bank act
broker dealer capac wish inform regard effect transact secur discuss report
contact place order capit market llc
public approv dominion secur inc member iiroc canadian recipi report design institut
ontario accredit investor british columbia alberta sophist purchas quebec similar permit purchas provinc
wish inform regard effect transact secur discuss report contact place order
dominion secur inc without way limit forego accept respons report dissemin canada
public approv europ limit el author prudenti regul author regul
conduct author fca prudenti regul author connect distribut unit kingdom materi gener
distribut unit kingdom retail client defin rule fca rbcel accept respons report dissemin
unit kingdom
materi distribut germani europ limit frankfurt branch regul bundesanstalt fr finanzdienstleistungsaufsicht bafin
receiv advic australia
materi distribut australia royal bank canada sydney branch abn afsl materi prepar
gener circul take account object financi situat need recipi accordingli recipi act
materi consid appropri materi regard object financi situat need materi relat acquisit
possibl acquisit particular financi product recipi australia obtain relev disclosur document prepar respect product
